AUTHOR INDEX

(P = Proceedings, S = Supplement)

AARONS, L., BALANT, L. & BOOBIS, A. Cost B15: modelling in drug development: 118

ABAD, S., MOACHON, L., BLANCHE, P., BAVOUX, F., SICARD, D. & SALMON-CÉRON, D. Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia: 456

ABDUL-MANAP, R. *see* WEBB, J.A.

AGABITI-ROSEI, E. *see* LEFRANDT, J.D.

AHOKOSKI, O., IRJALA, K., TAALIKKA, M., MANNINEN, P., HALONEN, K., KANGAS, L., SALMINEN, E., HUUPPONEN, R. & SCHEININ, H. Pharmokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men: 702

AKLILLU, E. *see* SCORDO, M.G.

AL ZAABI, M.A. *see* TANIRA, M.O.M.

AL-BARWANI, H. *see* TANIRA, M.O.M.

ALBERTSEN, B.K., SCHRODER, H., JAKOBSEN, P., MÜLLER, H.-J., CARLSEN, N.T. & SCHMIEGELOW, K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries: 433

ALEXANDER, G.J.M. *see* MÜCK, W.

ALLEN, D.J., WILSON, K., BRIGHT-THOMAS, R., MCDONNELL, B. & SINGH, S.D. The pharmacology of leukotriene D_4-induced inflammation in human skin: 466P

ALMOND, L. *see* HOGGARD, P.G.

AL-NAZWAN, N. *see* TANIRA, M.O.M.

ANGLARET, X. *see* MESSOU, E.

ANGUS, B. *see* SUPUTTAMONGKOL, Y.

ANTON, C. *see* COX, A.R.

ANTON, C. *see* FERNER, R.E.

ARAI, H. *see* TAGAWA, M.

ARMAND, J.P. *see* VAN KESTEREN, Ch.

ASHTON, M. *see* ZHANG, S.-Q.

BACK, D.J. *see* GIBBONS, E.

BACK, D.J. *see* HOGGARD, P.G.

BACK, D.J. *see* MEADEN, E.R.

BACK, D.J. *see* REYNOLDS, H.E.

BACK, D.J., KHOO, S.H., GIBBONS, S.E. & MERRY, C. The role of therapeutic drug monitoring in treatment of HIV infection: 89S

BACKMAN, J.T. *see* DESTA, Z.

BACKMAN, J.T. *see* WEN, X.

BALANT, L. *see* AARONS, L.

BARCLAY, M.L. *see* BEGG, E.J.

BARRINGTON, P. *see* VANMOLKOT, F.

BARRY, M. *see* M. HENNESSY, M.

BASSO, B. *see* TOFFOLI, G.

BATEMAN, D.N. *see* FERNER, R.E.

BAVOUX, F. *see* ABAD, S.

BAYOUMI, A.L. *see* TANIRA, M.O.M.

BECHGAARD, E. *see* LINDHARDT, K.

BECQUEMONT, L. *see* SIMON, T.

BÉGAUD, B. *see* LAGNAOUI, R.

BEGG, E.J., BARCLAY, M.L. & KIRKPATRICK, C.M.J. The therapeutic monitoring of antimicrobial agents: 35S

BEGG, E.J., MALPAS, T.J., HACKETT, L.P. & ILETT, K.F. Distribution of *R*- and *S*-methadone into human milk during multiple, medium to high oral dosing: 681

BEIJNEN, J.H. *see* KRUIJTZER, C.M.F.

BEIJNEN, J.H. *see* VAN KESTEREN, Ch.

BELLISSANT, E. & GIUDICELLI, J.-F. Pharmacokinetic–pharmacodynamic model for perinodoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients: 25

BENDSEN, J. *see* RIAHI, S.

BENJAMIN, N. *see* HICKS, S.L.

BERGIN, C. *see* M. HENNESSY, M.

BERTILSSON, L. *see* ROH, H.-K.

BEYSENS, A.J. *see* BOERSMA, H.H.

BLANCHE, P. *see* ABAD, S.

BLAUW, G.J., *see* VAN DER POST, J.

BOCK, J. *see* BUSS, N.

BOERSMA, H.H., THIMISTER, P.W.L., VAN HEERDE, W.L., KEMERINK, G.J., LIEM, H.M., HOFSTRA, L., LUX, P., JANSSEN, D., PAKBIERS, M.T., DOEVENDANS, P.A., STOLK, L.M.K., BEYSENS, A.J., REUTELINGSPERGER, C.P.M. & HEIDENDAL, G.A.K. Pharmacokinetics of the cell death marker 99mTc-phenthioate-Annexin V in patients with myocardial disease: 617P

BOIOCCHI, M. *see* TOFFOLI, G.

BOIX, O. *see* MÜCK, W.

BOL, C.J. *see* CRUL, M.

BONARD, D. *see* MESSOU, E.

BONATI, M. *see* IMPICCIATORE, P.

BONGAERTS, K.H. *see* WILKINSON, I.B.

BONHAM, J. *see* JOHNSON, T.N.

BONHAM, J.R. *see* DAVIS, K.R.

BOOBIS, A. *see* AARONS, L.

BOUKAIBA, R. *see* BOURNIQUE, B.

BOURNIQUE, B., LAMBERT, N., BOUKAIBA, R. & MARTINET, M. *In vitro* metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5, 6, 7, 8-tetrahydroindolizine 1-carboxamide): 53

BOWALGAHA, K. & MINERS, J.O. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes: 605

BOYLE, J., ROSTAMI-HODJEGAN, A., ELLIS, S.W. & TUCKER, G.T. Reference values for human microsomal protein per gram of liver: 471P

BRADSHAW, C.M. *see* PRETORIUS, J.L.

BRAUN, M. *see* WEBER, A.-A.

BREDDIN, H.K. *see* KLINKHARDT, U.

BREWER, T.G. *see* EDSTEIN, M.D.

BRIGHT-THOMAS, R. *see* ALLEN, D.J.

BRUCE, D.G. *see* DAVIS, T.M.E.

BRUCK, H. *see* WENZEL, R.R.

BRUNE, K. *see* LÖTSCH, J.

BUCHER, M. *see* KEES, F.

BUCK, H. & PARRY-BILLINGS, M. Discriminating measures of bronchodilator drug efficacy and potency: 245

BURGGRAAF, J. *see* KEMME, M.J.B.

BURGGRAAF, J. *see* TWISS, I.M.

BUSCH, E. & HUFNAGEL, A. Pharmacology of cerebral ischemia 2000: 613

BUSS, N., SNELL, P., BOCK, J., HSU, A. & JORGA, K. Saquinavir and ritonair pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration: 255

BUTLER, R., MORRIS, A.D. & STRUTHERS, A.D. Cigarette smoking in men and vascular responsiveness: 145

BUURMA, H., DE SMET, P.A.G.M., VAN DEN HOFF, O.P. & EGBERTS, A.C.G. Nature, frequency and determinants of prescription modifications in Dutch community pharmacies: 85

CALAFATTI, S.A., ORTIZ, R.A.M., DEGUER, M., MARTINEZ, M. & PEDRAZZOLI JR, J. Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers: 205

CAMIDGE, R. & PEASTON, R. Recommended dose antacids and severe hypercalcaemia: 341

CAMPBELL, T.J. & WILLIAMS, K.M.

© 2001 Blackwell Science Ltd

Therapeutic drug monitoring: antiarrhythmic drugs: 215
CARLSEN, N.T. *see* ALBERTSEN, B.K.
CASTELLANO, M. *see* LEFRANDT, J.D.
CAULFIELD, M. *see* WILSON, S.
CHAIKIN, P. *see* GILLEN, M.S.
CHAKRAPANI, A. *see* JOHNSON, T.N.
CHANCELLOR, M.B. *see* SATHYAN, G.
CHANDLER, B. *see* MEADEN, E.R.
CHARLES, B.G. *see* EDSTEIN, M.D.
CHEN, X.-P. *see* LIU, Z.-Q.
CHENG, V.C.C. *see* KUMANA, C.R.
CHENG, Z.-N. *see* LIU, Z.-Q.
CHEW, T.S. *see* LENNARD, L.
CHIBA, K. *see* SENDA, C.
CHIN, R. *see* ZHOU, S.
CHING, T.Y. *see* KUMANA, C.R.
CHIU, S.S. *see* KUMANA, C.R.
CHODJANIA, Y. *see* SIMON, T.
CHOONARA, I. *see* IMPICCIATORE, P.
CHRYSTYN, H. *see* NEWMAN, S.P.
CHUBB, P. *see* DAVIS, T.M.E.
CHUNG, J.-Y. *see* ROH, H.-K.
CIGHETTI, G. *see* PARONI, R.
CLARKE, S. *see* M. HENNESSY, M.
CLARKSON, A. *see* IMPICCIATORE, P.
COCKCROFT, J.R. *see* WILKINSON, I.B.
COHEN, A.F. *see* FRANSON, K.L.
COHEN, A.F. *see* KEMME, M.J.B.
COHEN, A.F. *see* TWISS, I.M.
COHEN, A.F. *see* VAN DER POST, J.
COLLIER, D. *see* WILSON, S.
COLLINS, R. *see* SCOTT, K.
COLOMBO, R. *see* PARONI, R.
COLUSSI, A.M. *see* TOFFOLI, G.
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP). Points to consider on switching between superiority and non-inferiority: 223
COMPTON, J., VAN AMELSVOORT, T. & MURPHY, D. HRT and its effect on normal ageing of the brain and dementia: 647
CORNET, F. *see* FRANSON, K.L.
CORONA, G. *see* TOFFOLI, G.
COX, A.R., ANTON, C., GOH, C.H.F., EASTER, M., LANGFORD, N.J. & FERNER, R.E. Adverse drug reactions in patients admitted to hospital identified by discharge ICD-10 codes and by spontaneous reports: 337
CRAMOND, T. *see* NISSEN, L.M.
CRESTEIL, T. *see* TRÉLUYER, J.-M.
CRUL, M., DE KLERK, G.J., SWART, M., VAN'T VEER, L.J., DE JONG, D., PALMER, P.A., BOL, C.J., TAN, H., DE GAST, G.C., *see* CRUL, M.& SCHELLENS, J.H.M. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyltransferase inhibitor R115777 in advanced cancer: 617P
DA POZZO, L.F. *see* PARONI, R.
DABIS FOR THE COTRIMO-CI ANRS 059 STUDY GROUP, F. *see* MESSOU, E.
DAHL, M.-L. *see* ROH, H.-K.
DAHL, M.-L. *see* SCORDO, M.G.
DALEY-YATES, P.T. *see* LIPWORTH, B.J.
DALLINGER, S. *see* RAINER, G.
DALLOW, N. *see* VANMOLKOT, F.
DALVI, S.S. *see* GOGTAY, N.J.
DALVI, S.S. *see* RANE, C.T.
DALY, A.K. & DAY, C.P. Candidate gene case-control association studies: advantages and potential pitfalls: 489
DARTIGUES, J.F. *see* LAGNAOUI, R.
DAVENPORT, A.P. *see* WILEY, K.E.
DAVIES, C.A. *see* HICKS, S.L.
DAVIS, K.R., PEARSON, H., MOAT, S., BONHAM, J.R. & DONNELLY, R. Acute hyperhomocysteinaemia affects pulse pressure but not microvascular vasodilator function: 327
DAVIS, T.M.E. *see* ZHANG, S.-Q.
DAVIS, T.M.E., JACKSON, D., DAVIS, W.A., BRUCE, D.G. & CHUBB, P. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study: 137
DAVIS, W.A. *see* DAVIS, T.M.E.
DAWSON, A.H. & WHYTE, I.M. Therapeutic drug monitoring in drug overdose: 97S
DAY, C.P. *see* DALY, A.K.
DE ABAJO, F.J. *see* GARCÍA, L.A.
DE BOER, A. *see* DE WOLF, M.
DE BOER, A. *see* TAMMINGA, W.J.
DE GAST, G.C. *see* CRUL, M.
DE GRAEFF, P.A. *see* HILLEGE, H.L.
DE HOON, J. *see* VANMOLKOT, F.
DE HOON, J.N.J.M., POPPE, K.A., THIJSSEN, H.H.W., STRUIJKER-BOUDIER, H.A.J. & VAN BORTEL, L.M.A.B. Dihydroergotamine: a discrepancy between arterial, arteriolar and pharmacokinetic data: 45
DE JONG, D. *see* CRUL, M.
DE KAM, M. *see* TWISS, I.M.
DE KAM, M.L., *see* VAN DER POST, J.
DE KAM, P.-J. *see* LEFRANDT, J.D.
DE KLERK, G.J. *see* CRUL, M.
DE LEIJ, L.F.M.H. JONKMAN, J.H.G.
DE SILVA, C.E. *see* FONSEKA, M.M.D.
DE SILVA, H.A., THABREW, I., PATHMESWARAN, A., SAPARAMADU, P.A.M., FONSEKA M.M.D. & DE SILVA, H.J. Lack of efficacy of Liv.52 in alcoholic liver disease: 469P
DE SILVA, H.J. *see* DE SILVA, H.A.
DE SILVA, H.J. *see* FONSEKA, M.M.D.
DE SMET, P.A.G.M. *see* BUURMA, H.
DE WOLF, M., STOLK, L.M., DEGRAEUWE, P.L., NIEMAN, F. & DE BOER, A. Prediction of the neonatal pharmacokinetics of gentamicin: 616P
DE ZEEUW, D. *see* HILLEGE, H.L.
DE ZEEUW, R.A. *see* TAMMINGA, W.J.
DEGRAEUWE, P.L. *see* DE WOLF, M.
DEGUER, M. *see* CALAFATTI, S.A.
DESTA, Z., KIVISTO, K.T., LILJA, J.J., BACKMAN, J.T., SOUKHOVA, N., NEUVONEN, P.J. & FLOCKHART, D.A. Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice: 399
DICKINS, M. *see* PALMER, J.L.
DIEMONT, W.L. *see* VAN PUIJENBROEK, E.P.
DODD, C.C., GOLDRING, C.E.P., KITTERINGHAM, N.R., PIRMOHAMED, M. & PARK, B.K. Pyrrolidine dithiocarbamate (PDTC) and its disulphide activate a g-glutamylcysteine synthetase (GCS) reporter gene: 482P
DOEVENDANS, P.A. *see* BOERSMA, H.H.
DONNELLY, R. *see* DAVIS, K.R.
DOSSO, M. *see* MESSOU, E.
DRENTH, B.F.H. *see* TAMMINGA, W.J.
DRUMMOND, P.D. & LIPNICKI, D.M. Repeated local administration of noradrenaline or saline inhibits thermal hyperalgesia in pain-sensitized human skin: 289

EADIE, M.J. Therapeutic drug monitoring – antiepileptic drugs: 115
EAMSILA, C. *see* EDSTEIN, M.D.
EARL, J.W. *see* NATH, C.E.
EASTER, M. *see* COX, A.R.
EDSBÄCKER, S. *see* THORSSON, L.
EDSTEIN, M.D., KOCISKO, D.A., BREWER, T.G., WALSH, D.S., EAMSILA, C. & CHARLES, B.G. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers: 663
EDWARDS, G. Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery: 463
EGBERTS, A.C.G. *see* BUURMA, H.
EGBERTS, A.C.G. *see* VAN PUIJENBROEK, E.P.
EICHLER, H.-G. *see* RAINER, G.
EKSBORG, S. *see* HALL, M.G.
ELLIS, S.W. *see* BOYLE, J.
ELSBY, R., POWELL, H., LOVATT, C.A., KITTERINGHAM, N.A., HENDERSON, C.J., WOLF, C.R. & PARK, B.K. Activities of UDP-glucuronosyltransferase and g-chglutamylcysteine synthetase in

glutathione S-transferase P1 null mice: 478P
ERNST, E. *see* FUGH-BERMAN, A.
ESSLINGER, H.-U. *see* KLINKHARDT, U.

FALLON, M. *see* LEFRANDT, J.D.
FÄRBER, L. *see* KEES, F.
FARELL, J. *see* GORDON, S.F.
FEDER, G. *see* WILSON, S.
FEELY, J. *see* WILLIAMS, D.
FEELY, J. *see* M. HENNESSY, M.
FEELY, J. *see* MAHMUD, M.
FEELY, J. *see* SCOTT, K.
FEELY, J. *see* WILLIAMS, D.
FEETAM, C.L. Anxiolytics: 463
FERNER, R.E. *see* COX, A.R.
FERNER, R.E., LANGFORD, N.J., ANTON, C., HUTCHINGS, A., BATEMAN, D.N. & ROUTLEDGE, P.A. Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example: 573
FIGULLA, H.-R. *see* LEDER, U.
FINDL, O. *see* RAINER, G.
FLOCKHART, D.A. *see* DESTA, Z.
FLOTEN, S.H. *see* LIU, M.-H.
FONAGER, K. *see* RIAHI, S.
FONSEKA M.M.D. *see* DE SILVA, H.A.
FONSEKA, M.M.D., SENEVIRATNE, S.L., DE SILVA, C.E., GUNATILAKE, S.B. & DE SILVA, H.J. Yellow oleander poisoning in Sri Lanka: outcome in a secondary care hospital: 470P
FOURRIER, A. *see* LAGNAOUI, R.
FOWLER, S.J., ORR, L.C., WILSON, A.M., SIMS, E.J. & LIPWORTH, B.J. Dose–response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate: 93
FRANSON, K.L., CORNET, F., VAN GERVEN, J.M.A. & COHEN, A.F. Teaching Resource Centre: Teaching Clinical Pharmacology from a pathophysiological perspective to medical students using a database of uniform visual images: 623P
FUGH-BERMAN, A. & ERNST, E. Herb–drug interactions: Review and assessment of report reliability: 587
FUJII, H. *see* SENDA, C.
FUJII, T. *see* TAGAWA, M.
FUJIMURA, A. *see* HISHIKAWA, S.
FUJIMURA, A. *see* SASAKI, M.
FUNCK-BRENTANO, C. *see* SIMON, T.

GARCÍA, L.A., RODRÍGUEZ, S., HERNÁNDEZ-DÍAZ, F.J. & DE ABAJO, F.J. Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies: 563
GARDNER-MEDWIN, J.M., MACDONALD, I.A., TAYLOR, J.Y., RILEY, P.H. & POWELL, R.J. Seasonal differences in finger skin temperature and microvascular blood flow in healthy men and women are exaggerated in women with primary Raynaud's phenomenon: 17
GEISSLINGER, G. *see* GRÖSCH, S.
GEISSLINGER, G. *see* LÖTSCH, J.
GEORGOPOULOS, M. *see* RAINER, G.
GIBBONS, E., REYNOLDS, H.E., LLOYD, J., TJIA, J., KHOO, S. & BACK, D.J. Therapeutic drug monitoring of anti-HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors: a report on the Liverpool TDM service: 480P
GIBBONS, S.E. *see* BACK, D.J.
GIBBONS, S.E. *see* REYNOLDS, H.E.
GIBSON, A. *see* PALMER, J.L.
GILLEN, M.S., MILLER, B., CHAIKIN, P. & MORGANROTH, J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval: 201
GIUDICELLI, J.-F. *see* BELLISSANT, E.
GIZURARSON, S. *see* LINDHARDT, K.
GOGTAY, N.J. *see* RANE, C.T.
GOGTAY, N.J., KSHIRSAGAR, N.A. & DALVI, S.S. Therapeutic drug monitoring in a developing country: an overview: 103S
GOH, C.H.F. *see* COX, A.R.
GOLDBERG, M.R., TOMASKO, D., LEE, M.DE, OLAH, R.LOWRY, ZHAO, L., VYAS, Y., HALPIN, T.V., KARI, J. & JAMES, K.P. Influence of β-adrenoreceptor antagonists on the pharmacokinetics of rizatriptan, a 5-$HT_{1B/1D}$ agonist: differential effects of propanolol, nadolol and metoprolol: 69
GOLDRING, C.E.P. *see* DODD, C.C.
GOLDSTEIN, J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily: 349
GORDON, S.F., NAISBITT, D.J., FARELL, J., PIRMOHAMED, M. & PARK, B.K. The role of cellular conjugates and differential binding in the immunogenicity of sulphamethoxazole: 483P
GÖTTLER, M. *see* SCHNEEWEISS, S.
GRAFF, J. *see* KLINKHARDT, U.
GROBBEE, D.E. *see* HILLEGE, H.L.
GROBECKER, H. *see* KEES, F.
GRÖSCH, S., NIEDERBERGER, E., LÖTSCH, J., SKARKE, C. & GEISSLINGER, G. A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene: 711
GROSS, A.S. Best practice in therapeutic drug monitoring: 5S
GULLSTÉN, H. *see* RAUNIO, H.

GUNATILAKE, S.B. *see* FONSEKA, M.M.D.
GUNNING, R. *see* NATH, C.E.
GUPTA, S.K. *see* SATHYAN, G.

HACKETT, L.P. *see* BEGG, E.J.
HAI, T.N. *see* ZHANG, S.-Q.
HALL, M.G., WILKS, M.F., PROVAN, W.M., EKSBORG, S. & LUMHOLTZ, B. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers: 169
HALONEN, K. *see* AHOKOSKI, O.
HALPIN, T.V. *see* GOLDBERG, M.R.
HAMON, B. *see* SIMON, T.
HAQ, I.U. *see* JACKSON, P.R.
HARDER, S. *see* KLINKHARDT, U.
HARGREAVE F.E. *see* PARAMESWARAN, K.
HASAN, R. *see* MÜCK, W.
HASFORD, J. *see* SCHNEEWEISS, S.
HAUEISEN, J. *see* LEDER, U.
HAUSBERG, M. *see* LEFRANDT, J.D.
HE, G.-W. *see* LIU, M.-H.
HEDAYETULLAH, N.S. *see* KOCH, K.M.
HEIDENDAL, G.A.K. *see* BOERSMA, H.H.
HEITMANN, J. *see* LEFRANDT, J.D.
HENDERSON, C.J. *see* ELSBY, R.
HENNESSY, M., MOTUMISE, K., KELLEHER, D., CLARKE, S., BERGIN, C., MULCAHY, F., FEELY, J. & BARRY, M. The role of the multidrug transporter P-glycoprotein in HIV disease: 465P
HERINGS, R.M.C. *see* VAN DER LINDEN, P.D.
HERNÁNDEZ-DÍAZ, F.J. *see* GARCÍA, L.A.
HICKS, S.L., DAVIES, C.A., ROCKS, S.A., JOHNSTON, A., WINYARD, P. & BENJAMIN, N. Increase in gastric S-nitrosothiols following ingestion of inorganic nitrate in humans: 474P
HIGUCHI, M. *see* TAGAWA, M.
HILLEGE, H.L., DE GRAEFF, P.A., VAN GILST, W.H., VAN VELDHUISEN, D.J., NAVIS, G., GROBBEE, D.E. & DE ZEEUW, D. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: 621P
HILLIER, C. *see* PETRIE, M.C.
HIPPIUS, M. *see* SCHNEEWEISS, S.
HISHIKAWA, S., KOBAYASHI, E., SUGIMOTO, K.-I., MIYATA, M. & FUJIMURA, A. Diurnal variation in the biliary excretion of flomoxef in patients

with percutaneous transhepatic biliary drainage: 65
HOFFMANN, A.-K. *see* SCHNEEWEISS, S.
HOFMANN, U. *see* WEBB, J.A.
HOFSTRA, L. *see* BOERSMA, H.H.
HOGGARD, P.G. *see* MEADEN, E.R.
HOGGARD, P.G., KEWN, S., LLOYD, J., SALES, S., ALMOND, L., MEADEN, E.R., JONES, T., WILKINS, E., SABIN, C., PILLAY, D., KHOO, S.H. & BACK, D.J. Intracellular drug/endogenous nucleoside triphosphate ratios in HIV infected patients on lamivudine and abacavir as part of combination therapy (Malibu study): 466P
HOHLFELD, T. *see* WEBER, A.-A.
HOLFORD, N.H.G. Target concentration intervention: beyond Y2K: 55S
HOLT, D.W. *see* JOHNSTON, A.
HOUSTON, J.B. *see* TUCKER, G.T.
HSU, A. *see* BUSS, N.
HUANG, S.-L. *see* LIU, Z.-Q.
HUANG, S.-M. *see* TUCKER, G.T.
HUCH, A. *see* RICHTER, C.
HUCH, R. *see* RICHTER, C.
HUFNAGEL, A. *see* BUSCH, E.
HUGHES, A.M. & WATKINS, C. The intravenous tyramine pressor test in man: a dose escalation regimen which is not associated with tachyphylaxis: 479P
HUNT, S.J., ROSTAMI-HODJEGAN, A., LENNARD, M.S., PRATT, P. & SEIVEWRIGHT, N. Investigating the factors influencing dosage change in patients undergoing methadone maintenance therapy: 473P
HUONG, D.X. *see* ZHANG, S.-Q.
HUTCHINGS, A. *see* FERNER, R.E.
HUUPPONEN, R. *see* AHOKOSKI, O.
HVILSTED-RASMUSSEN, L. *see* RIAHI, S.

IDO, T. *see* TAGAWA, M.
IGARASHI, T. *see* SENDA, C.
ILETT, K.F. *see* BEGG, E.J.
ILETT, K.F. *see* ZHANG, S.-Q.
IMPICCIATORE, P., CHOONARA, I., CLARKSON, A., PROVASI, D., PANDOLFINI, C. & BONATI, M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies: 77
INGELMAN-SUNDBERG, M. *see* SCORDO, M.G.
IRJALA, K. *see* AHOKOSKI, O.
ITOH, M. *see* TAGAWA, M.
IWATA, R. *see* TAGAWA, M.

JACKSON, D. *see* DAVIS, T.M.E.
JACKSON, P.R., WALLIS, E.J., HAQ, I.U. & RAMSAY, L.E. Statins for primary prevention: at what coronary risk is safety assured?: 439
JAILLON, P. *see* SIMON, T.
JAKOBSEN, P. *see* ALBERTSEN, B.K.
JAMES, K.P. *see* GOLDBERG, M.R.
JANSSEN, D. *see* BOERSMA, H.H.
JEFFERYS, D.B. The regulation of medical devices and the role of the Medical Devices Agency: 229
JEWELL, D. *see* KOCH, K.M.
JIANG, C.-H. *see* LIU, Z.-Q.
JICK, H. Meyler's side-effects of drugs, 14th edition: 461
JICK, H. *see* MEIER, C.R.
JICK, H., VASILAKIS-SCARAMOZZA, C. & JICK, S.S. Live attenuated polio vaccine and the risk of intussusception: 451
JICK, S.S. *see* JICK, H.
JOHNSEN, S.P. *see* RIAHI, S.
JOHNSON, T.N. *see* ROW, E.
JOHNSON, T.N., ROSTAMI-HODJEGAN, A., MATTHEWS, A., TUCKER, G.T., CHAKRAPANI, A., WRAITH, E. & BONHAM, J. An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocysteinuria: 474P
JOHNSTON, A. & HOLT, D.W. Immunosuppressant drugs – the role of therapeutic drug monitoring: 61S
JOHNSTON, A. *see* HICKS, S.L.
JOHNSTON, A. *see* WILSON, S.
JONES, T. *see* HOGGARD, P.G.
JONKMAN, J.H.G. JONKMAN, J.H.G.
JORGA, K. *see* BUSS, N.
JOSEPH, L. *see* RAHME, E.

KÄLLÉN, A. *see* THORSSON, L.
KAMALI, F. *see* WEBB, J.A.
KANGAS, L. *see* AHOKOSKI, O.
KANO, M. *see* TAGAWA, M.
KARI, J. *see* GOLDBERG, M.R.
KASTELIK, J.A. *see* MORICE, A.H.
KEERATITHAKUL, D. *see* SUPUTTAMONGKOL, Y.
KEES, F., FÄRBER, L., BUCHER, M., MAIR, G., MÖRIKE, K. & GROBECKER, H. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers: 705
KELLEHER, D. *see* M. HENNESSY, M.
KELLY, A. *see* WILLIAMS, D.
KEMERINK, G.J. *see* BOERSMA, H.H.
KEMME, M.J.B., BURGGRAAF, J., SCHOEMAKER, R.D. & COHEN, A.F. No influence of acute hypertriglyceridemia on plasma t-PA in healthy male volunteers: 626P
KERSEY, K.E. *see* KOCH, K.M.
KESTELL, P. *see* ZHOU, S.
KEWN, S. *see* HOGGARD, P.G.
KHOO, S. *see* GIBBONS, E.
KHOO, S.H. *see* BACK, D.J.
KHOO, S.H. *see* HOGGARD, P.G.
KHOO, S.H. *see* MEADEN, E.R.
KHOO, S.H. *see* REYNOLDS, H.E.
KIRCHMAIER, C.M. *see* KLINKHARDT, U.
KIRKPATRICK, C.M.J. *see* BEGG, E.J.
KISS, B. *see* RAINER, G.
KITTERINGHAM, N.A. *see* ELSBY, R.
KITTERINGHAM, N.R. *see* DODD, C.C.
KIVISTÖ, K.T. *see* DESTA, Z.
KIVISTÖ, K.T. *see* WEN, X.
KLINKHARDT, U., GRAFF, J., WESTRUP, D., KIRCHMAIER, C.M., ESSLINGER, H.-U., BREDDIN, H.K. & HARDER, S. Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects: 297
KOBAYASHI, E. *see* HISHIKAWA, S.
KOBAYASHI, K. *see* SENDA, C.
KOCH, K.M., RICCI, B.M., HEDAYETULLAH, N.S., JEWELL, D. & KERSEY, K.E. Effect of alosetron on theophylline pharmacokinetics: 596
KOCISKO, D.A. *see* EDSTEIN, M.D.
KOMEMUSHI, S. *see* TAGAWA, M.
KONG, S.X. *see* RAHME, E.
KONG, Y. *see* KUMANA, C.R.
KOU, M. *see* KUMANA, C.R.
KOUABENA, H. *see* MESSOU, E.
KRAPPWEIS, J. *see* SCHNEEWEISS, S.
KRUIJTZER, C.M.F., ROSING, H., ten BOKKEL HUININK, W.W., SWART, M., BEIJNEN, J.H. & SCHELLENS, J.H.M. The effect of GF 120918 (GF) on the oral bioavailability (*F*) and systemic clearance (CL) of topotecan: 619P
KSHIRSAGAR, N.A. *see* GOGTAY, N.J.
KSHIRSAGAR, N.A. *see* RANE, C.T.
KUMANA, C.R., CHING, T.Y., KONG, Y., MA, E.C.W., KOU, M., LEE, R.A., CHENG, V.C.C., CHIU, S.S. & SETO, W.-H. Curtailing unnecessary vancomycin usage in a hospital with high rates of methicillin resistant *Staphylococcus aureus* infections: 427

LAGNAOUI, R., MOORE, N., DARTIGUES, J.F., FOURRIER, A. & BÉGAUD, B. Benzodiazepine use and wine consumption in the French elderly., 455
LAMBERT, N. *see* BOURNIQUE, B.
LANCASTER, D.L. *see* LENNARD, L.
LANG, P. *see* RICHTER, C.
LANGFORD, N.J. *see* COX, A.R.
LANGFORD, N.J. *see* FERNER, R.E.
LANGLEY, R.W. *see* PRETORIUS, J.L.
LEDER, U., HAUEISEN, J., SCHWARZ,

G., LIEHR, M. & FIGULLA, H.-R. (±)-sotalol alters neither the shape of the T wave downslope nor the U wave; a magnetocardiographic study: 715
LEE, M.DE *see* GOLDBERG, M.R.
LEE, R.A. *see* KUMANA, C.R.
LEFRANDT, J.D., HEITMANN, J., SEVRE, K., CASTELLANO, M., HAUSBERG, M., FALLON, M., URBIGKEIT, A., ROSTRUP, M., AGABITI-ROSEI, E., RAHN, K.H., MURPHY, M., ZANNAD, F., DE KAM, P.-J. & SMIT, A.J. Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension: 687
LELORIER, J. *see* RAHME, E.
LENNARD, L. Therapeutic drug monitoring of cytotoxic drugs: 75S
LENNARD, L., CHEW, T.S. & LILLEYMAN, J.S. Human thiopurine methyltransferase activity varies with red blood cell age: 539
LENNARD, L., LANCASTER, D.L., PATEL, N. & LILLEYMAN, J.S. Comparison of red and white cell 6-thioguanine nucleotide concentrations in children with lymphoblastic leukaemia on 6-mercaptopurine and 6-thioguanine therapy: 476P
LENNARD, M.S. *see* HUNT, S.J.
LENNARD, M.S. *see* ROW, E.
LEUFKENS, H.G.M. *see* VAN PUIJENBROEK, E.P.
LEUFKENS, H.M.G. *see* VAN DER LINDEN, P.D.
LEV, A. *see* PARONI, R.
LEWIS, J.A. Switching between superiority and non-inferiority: an introductory note: 221
LIEHR, M. *see* LEDER, U.
LIEM, H.M. *see* BOERSMA, H.H.
LILJA, J.J. *see* DESTA, Z.
LILLEYMAN, J.S. *see* LENNARD, L.
LILLEYMAN, J.S. *see* LENNARD, L.
LIMMROTH, V. & MICHEL, M.C. The prevention of migraine: a critical review with special emphasis on β-adrenoceptor blockers: 237
LINDHARDT, K., GIZURARSON, S., STEFÁNSSON, S.B., ÓLAFSSON, D.R. & BECHGAARD, E. Electroencephalographic effects and serum concentrations after intranasal and intravenous administration of diazepam to healthy volunteers: 521
LIPNICKI, D.M. *see* DRUMMOND, P.D.
LIPWORTH, B.J. & DALEY-YATES, P.T. Systemic bioavailabilty of fluticasone proprionate: 457
LIPWORTH, B.J. *see* FOWLER, S.J.
LIU, M.-H., FLOTEN, S.H., YANG, Q. & HE, G.-W. Inhibition of vasoconstriction by AJ-2615, a novel calcium antagonist with α_1-adrenergic receptor blocking activity in human conduit arteries used as bypass grafts: 279
LIU, Z.-Q., CHENG, Z.-N., HUANG, S.-L., CHEN, X.-P., OU-YANG, D.-S., JIANG, C.-H. & ZHOU, H.-H. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects: 96
LLOYD, J. *see* GIBBONS, E.
LLOYD, J. *see* HOGGARD, P.G.
LÖFDAHL, C.-G. *see* THORSSON, L.
LÖTSCH, J. *see* GRÖSCH, S.
LÖTSCH, J., MUTH-SELBACH, U., TEGEDER, I., BRUNE, K. & GEISSLINGER, G. Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate: 387
LOVATT, C.A. *see* ELSBY, R.
LUMHOLTZ, B. *see* HALL, M.G.
LUX, P. *see* BOERSMA, H.H.

MA, E.C.W. *see* KUMANA, C.R.
MACCALLUM, H. *see* WILKINSON, I.B.
MACDONALD, I.A. *see* GARDNER-MEDWIN, J.M.
MAEDA, A. *see* SASAKI, M.
MAHMUD, M. & FEELY, J. Effect of wine on the pulse: difference between acute and chronic ingestion — studies in Dublin 1839–2001: 467P
MAIR, G. *see* KEES, F.
MALPAS, T.J. *see* BEGG, E.J.
MANNINEN, P. *see* AHOKOSKI, O.
MARTINET, M. *see* BOURNIQUE, B.
MARTINEZ, M. *see* CALAFATTI, S.A.
MATHOT, R.A.A. *see* VAN KESTEREN, Ch.
MATSUDA, M. *see* TAGAWA, M.
MATTHEWS, A. *see* JOHNSON, T.N.
MAXWELL, S.R. *see* MCENIERY, C.M.
MCCOLM, J. *see* VANMOLKOT, F.
MCDONALD, J.E. *see* PETRIE, M.C.
MCDONNELL, B. *see* ALLEN, D.J.
MCENIERY, C.M. *see* WILKINSON, I.B.
MCENIERY, C.M., WILKINSON, I.B., MAXWELL, S.R. & WEBB, D.J. Reproducibility and use of handgrip exercise in the assessment of vascular regulation: 488P
MCLACHLAN, A.J. *see* NATH, C.E.
MCMURRAY, J.J.V. *see* PETRIE, M.C.
MEADEN, E.R. *see* HOGGARD, P.G.
MEADEN, E.R., HOGGARD, P.G., CHANDLER, B., KHOO, S.H. & BACK, D.J. Expression of the efflux transporters P-gp and MRP in Caucasian and black African healthy volunteers and HIV infected Caucasians: 481P
MEIER, C.R., SCHLIENGER, R.G. & JICK, H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction: 179
MEIJER, P., VAN GINNEKEN, E.E.M., RAAIJMAKERS, F., RUSSEL, F., SMITS, P. & RONGEN, G.A. A role for ATP-sensitive potassium channels in ATP-induced forearm vasodilation: 620P
MEINARDI, M.M.H.M. *see* MULDER, W.M.C.
MEINARDI, M.M.H.M. *see* RODER, E.
MELLEMKJAER, J.H. *see* TOFT, H.
MENAPACE, R. *see* RAINER, G.
MERRY, C. *see* BACK, D.J.
MESSOU, E., ANGLARET, X., BONARD, D., KOUABENA, H., N'DRI-YOMAN, T., DOSSO, M. & DABIS, F. for the COTRIMO-CI ANRS 059 STUDY GROUP. The effect of cotrimoxazole coadministrated with antituberculous drugs on serum transaminases in HIV-infected adults from the Ivory Coast: 611
MICHEL, M.C. *see* LIMMROTH, V.
MICHEL, M.C. *see* WENZEL, R.R.
MIKUS, G. *see* WEBB, J.A.
MILLER, B. *see* GILLEN, M.S.
MINAMI, H. *see* SENDA, C.
MINERS, J.O. *see* BOWALGAHA, K.
MITCHELL, P.B. Therapeutic drug monitoring of psychotropic medications: 45S
MIYATA, M. *see* HISHIKAWA, S.
MIZUKI, Y. *see* TAGAWA, M.
MOACHON, L. *see* ABAD, S.
MOAT, S. *see* DAVIS, K.R.
MONTORSI, F. *see* PARONI, R.
MOORE, N. *see* LAGNAOUI, R.
MORGANROTH, J. *see* GILLEN, M.S.
MORICE, A.H., KASTELIK, J.A. & THOMPSON, R. Cough challenge in the assessment of cough reflex: 365
MÖRIKE, K. *see* KEES, F.
MORRIS, A.D. *see* BUTLER, R.
MORTON, J.J. *see* PETRIE, M.C.
MOTUMISE, K. *see* M. HENNESSY, M.
MOULY, S. & PAINE, M.F. Effect of grapefruit juice on the dipsposition of omeprazole: 216
MÜCK, W., NEAL, D.A.J., BOIX, O., VOITH, B., HASAN, R. & ALEXANDER, G.J.M. Tacrolimus/cerivastatin interaction study in liver transplant recipients: 213
MUCKLOW, J.C. Adverse drug reactions: 461
MUCKLOW, J.C. Continuing Medical Education in Clinical Pharmacology and Therapeutics: report of a questionnaire survey: 9
MULCAHY, F. *see* M. HENNESSY, M.
MULDER, W.M.C. *see* RODER, E.
MULDER, W.M.C., MEINARDI, M.M.H.M. & VAN BOXTEL,

C.J. Outpatient clinic for drug-related problems: 622P
MÜLLER, H.-J. *see* ALBERTSEN, B.K.
MURPHY, D. *see* COMPTON, J.
MURPHY, M. *see* LEFRANDT, J.D.
MURRAY, G.D. Switching between superiority and non-inferiority: 219
MUTH-SELBACH, U. *see* LÖTSCH, J.

N'DRI-YOMAN, T. *see* MESSOU, E.
NAISBITT, D. *see* WILLIAMS, D.
NAISBITT, D.J. *see* GORDON, S.F.
NATH, C.E., MCLACHLAN, A.J., SHAW, P.J., GUNNING, R. & EARL, J.W. Population pharmacokinetics of amphotericin B in children with malignant diseases: 671
NAVIS, G. *see* HILLEGE, H.L.
NEAL, D.A.J. *see* MÜCK, W.
NEUVONEN, P.J. *see* DESTA, Z.
NEUVONEN, P.J. *see* WEN, X.
NEWMAN, S.P. & CHRYSTYN, H. Lung distribution of inhaled drugs: 716
NEWTON, P.N. *see* SUPUTTAMONGKOL, Y.
NIEDERBERGER, E. *see* GRÖSCH, S.
NIEMAN, F. *see* DE WOLF, M.
NISSEN, L.M., TETT, S.E., CRAMOND, T., WILLIAMS, B. & SMITH, M.T. Opioid analgesic prescribing and use – an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital: 693
NOORDZIJ, L.A.W. *see* VAN DER POST, J.
NOUYRIGAT, E. *see* SIMON, T.

OH, D.-Y. *see* ROH, H.-K.
OKAMURA, N. *see* TAGAWA, M.
ÓLAFSSON, D.R. *see* LINDHARDT, K.
OLAH, R.LOWRY *see* GOLDBERG, M.R.
OLSEN, J.H. *see* TOFT, H.
OOSTERHUIS, B. *see* TAMMINGA, W.J.
ORR, L.C. *see* FOWLER, S.J.
ORTIZ, R.A.M. *see* CALAFATTI, S.A.
OU-YANG, D.-S. *see* LIU, Z.-Q.

PAINE, M.F. *see* MOULY, S.
PAKBIERS, M.T. *see* BOERSMA, H.H.
PALMER, J.L., SCOTT, R.J., GIBSON, A., DICKINS, M. & PLEASANCE, S. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A): 555
PALMER, P.A. *see* CRUL, M.
PANDOLFINI, C. *see* IMPICCIATORE, P.
PARAMESWARAN, K. & HARGREAVE F.E. The use of sputum cell counts to evaluate asthma medications: 121
PARK, B.K. *see* DODD, C.C.
PARK, B.K. *see* ELSBY, R.
PARK, B.K. *see* GORDON, S.F.
PARK, C.-S. *see* ROH, H.-K.
PARK, K. *see* WILLIAMS, D.
PARONI, R., SALONIA, A., LEV, A., DA POZZO, L.F., CIGHETTI, G., MONTORSI, F., RIGATTI, P. & COLOMBO, R. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma: 273
PARRY-BILLINGS, M. *see* BUCK, H.
PATEL, N. *see* LENNARD, L.
PATHMESWARAN, A. *see* DE SILVA, H.A.
PAXTON, J.W. *see* ZHOU, S.
PEARSON, H. *see* DAVIS, K.R.
PEASTON, R. *see* CAMIDGE, R.
PECK, R. *see* VANMOLKOT, F.
PEDRAZZOLI JR, J. *see* CALAFATTI, S.A.
PELKONEN, O. *see* RAUNIO, H.
PENNING-VAN-BEEST, F.J.A., VAN MEEGEN, E., ROSENDAAL, F.R., STRICKER, B.H.Ch. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs: 616P
PETRIE, M.C., MCDONALD, J.E., HILLIER, C., MORTON, J.J. & MCMURRAY, J.J.V. Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans: 165
PHILIPP, TH. *see* WENZEL, R.R.
PHILLIPS, M. *see* PRETORIUS, J.L.
PIETERS, M.S.M., *see* VAN DER POST, J.
PILLAY, D. *see* HOGGARD, P.G.
PIRMOHAMED, M *see* GORDON, S.F.
PIRMOHAMED, M. Pharmacogenetics and pharmacogenomics: 345
PIRMOHAMED, M. *see* DODD, C.C.
PIRMOHAMED, M. *see* WILLIAMS, D.
PLEASANCE, S. *see* PALMER, J.L.
POIRIER, J.M. *see* SIMON, T.
POLAK, K. *see* RAINER, G.
PONS, G. *see* TRÉLUYER, J.-M.
POPPE, K.A. *see* DE HOON, J.N.J.M.
POULTER, N. *see* WILSON, S.
POWELL, H. *see* ELSBY, R.
POWELL, R.J. *see* GARDNER-MEDWIN, J.M.
PRATT, P. *see* HUNT, S.J.
PRETORIUS, J.L., PHILLIPS, M., LANGLEY, R.W., SZABADI, E. & BRADSHAW, C.M. Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects: 322
PROVAN, W.M. *see* HALL, M.G.
PROVASI, D. *see* IMPICCIATORE, P.
PUKRITTAYAKAMEE, S. *see* SUPUTTAMONGKOL, Y.

RAAIJMAKERS, F. *see* MEIJER, P.
RAHME, E., JOSEPH, L., KONG, S.X., WATSON, D.J. & LELORIER, J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients: 185
RAHN, K.H. *see* LEFRANDT, J.D.
RAINER, G., KISS, B., DALLINGER, S., FINDL, O., GEORGOPOULOS, M., VASS, C., MENAPACE, R., POLAK, K., EICHLER, H.-G., WOLZT, M. & SCHMETTERER, L. A double masked placebo controlled study on the effect of nifedipine on optic nerve blood flow and visual field function in patients with open angle glaucoma: 210
RAMSAY, L.E. *see* JACKSON, P.R.
RANE, C.T., DALVI, S.S., GOGTAY, N.J., SHAH, P.U. & KSHIRSAGAR, N.A. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic–clonic epilepsy: 193
RASAMEESORAJ, M. *see* SUPUTTAMONGKOL, Y.
RAUNIO, H., RAUTIO, A., GULLSTÉN, H. & PELKONEN, O. Polymorphisms of CYP2A6 and its practical consequences: 357
RAUTIO, A. *see* RAUNIO, H.
RAYMOND, E. *see* VAN KESTEREN, Ch.
REUTELINGSPERGER, C.P.M. *see* BOERSMA, H.H.
REY, E. *see* TRÉLUYER, J.-M.
REYNOLDS, H.E. *see* GIBBONS, E.
REYNOLDS, H.E., TJIA, J.F., GIBBONS, S.E., KHOO, S.H. & BACK, D.J. Simultaneous determination of four HIV protease inhibitors by h.p.l.c.-MS/MS for use in a therapeutic drug monitoring service: 481P
RIAHI, S., FONAGER, K., TOFT, E., HVILSTED-RASMUSSEN, L., BENDSEN, J., JOHNSEN, S.P., TOFT, H. & SORENSEN, H. Use of lipid-lowering drugs during 1991–98 in Northern Jutland, Denmark: 307
RICCI, B.M. *see* KOCH, K.M.
RICHTER, C., SITZMANN, J., LANG, P., WEITZEL, H., HUCH, A. & HUCH, R. Excretion of low molecular weight heparin in human milk: 708
RIETHLING, A.-K. *see* SCHNEEWEISS, S.
RIGATTI, P. *see* PARONI, R.

RILEY, P.H. *see* GARDNER-MEDWIN, J.M.
ROBIEUX, I. *see* TOFFOLI, G.
ROCKS, S.A. *see* HICKS, S.L.
RODER, E., MULDER, W.M.C., MEINARDI, M.M.H.M. & VAN BOXTEL, C.J. Reproducibility and concentration-response relations of intracutaneous skin tests with histamine and compound 48/80: 624P
RODRÍGUEZ, S. *see* GARCÍA, L.A.
ROH, H.-K., CHUNG, J.-Y., OH, D.-Y., PARK, C.-S., SVENSSON, J.-O., DAHL, M.-L. & BERTILSSON, L. Plasma concentrations of haloperidol are related to *CYP2D6* genotype at low, but not high doses of haloperidol in Korean schizophrenic patients: 265
RONGEN, G.A. *see* MEIJER, P.
ROSENDAAL, F.R. *see* PENNING-VAN-BEEST, F.J.A.
ROSING, H. *see* KRUIJTZER, C.M.F.
ROSTAMI-HODJEGAN, A *see* YANG, J.S.
ROSTAMI-HODJEGAN, A. *see* BOYLE, J.
ROSTAMI-HODJEGAN, A. *see* HUNT, S.J.
ROSTAMI-HODJEGAN, A. *see* JOHNSON, T.N.
ROSTAMI-HODJEGAN, A. *see* WEBB, J.A.
ROSTAMI-HODJEGAN, A. *see* YANG, J.S.
ROSTRUP, M. *see* LEFRANDT, J.D.
ROUTLEDGE, P.A. *see* FERNER, R.E.
ROW, E., STACHULSKI, A.V., JOHNSON, T.N. & LENNARD, M.S. Fruit juices and red wine inhibit human intestinal and hepatic cytochrome P450, CYP3A: 475P
RUSSEL, F. *see* MEIJER, P.
RÜTHEMANN, J. *see* WENZEL, R.R.

SABIN, C. *see* HOGGARD, P.G.
SAKAMOTO, K. *see* SASAKI, M.
SALES, S. *see* HOGGARD, P.G.
SALMINEN, E. *see* AHOKOSKI, O.
SALMON-CÉRON, D. *see* ABAD, S.
SALONIA, A. *see* PARONI, R.
SAPARAMADU, P.A.M. *see* DE SILVA, H.A.
SASAKI, H. *see* TAGAWA, M.
SASAKI, M., MAEDA, A., SAKAMOTO, K. & FUJIMURA, A. Effect of bile acids on absorption of nitrendipine in healthy subjects: 699
SASAKI, Y. *see* SENDA, C.
SATHYAN, G., CHANCELLOR, M.B. & GUPTA, S.K. Effect of OROS® controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride: 409
SCHÄFERS, R.F. *see* WENZEL, R.R.
SCHEININ, H. *see* AHOKOSKI, O.
SCHELLENS, J.H.M. *see* CRUL, M.
SCHELLENS, J.H.M. *see* KRUIJTZER, C.M.F.
SCHELLENS, J.H.M. *see* VAN KESTEREN, Ch.
SCHLIENGER, R.G. *see* MEIER, C.R.
SCHMETTERER, L. *see* RAINER, G.
SCHMIEGELOW, K. *see* ALBERTSEN, B.K.
SCHNEEWEISS, S., GÖTTLER, M., HASFORD, J., SWOBODA, W., HIPPIUS, M., HOFFMANN, A.-K., RIETHLING, A.-K. & KRAPPWEIS, J. First results from an intensified monitoring system to estimate drug related hospital admissions: 196
SCHOEMAKER, R.D. *see* KEMME, M.J.B.
SCHRODER, H. *see* ALBERTSEN, B.K.
SCHRÖR, K. *see* WEBER, A.-A.
SCHWARZ, G. *see* LEDER, U.
SCHWIPPERT, B. *see* WEBER, A.-A.
SCORDO, M.G., AKLILLU, E., YASAR, U., DAHL, M.-L., SPINA, E. & INGELMAN-SUNDBERG, M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population: 447
SCOTT, K., COLLINS, R. & FEELY, J. Does an increase in dietary salt affect sodium lithium counter-transport (SLC)?: 468P
SCOTT, R.J. *see* PALMER, J.L.
see CRUL, M. *see* CRUL, M.
SEIVEWRIGHT, N. *see* HUNT, S.J.
SENDA, C., YAMAURA, Y., KOBAYASHI, K., FUJII, H., MINAMI, H., SASAKI, Y., IGARASHI, T. & CHIBA, K. Influence of the *CYP2D6*10* allele on the metabolism of mexiletine by human liver microsomes: 100
SENEVIRATNE, S.L. *see* FONSEKA, M.M.D.
SETO, W.-H. *see* KUMANA, C.R.
SEVRE, K. *see* LEFRANDT, J.D.
SHAH, P.U. *see* RANE, C.T.
SHAW, P.J. *see* NATH, C.E.
SHENFIELD, G.M. Therapeutic drug monitoring beyond 2000: 3S
SHENFIELD, G.M. Therapeutic drug monitoring: Introduction: 1S
SICARD, D. *see* ABAD, S.
SIMON, T., BECQUEMONT, L., HAMON, B., NOUYRIGAT, E., CHODJANIA, Y., POIRIER, J.M., FUNCK-BRENTANO, C. & JAILLON, P. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers: 601
SIMONIAN, S. *see* VOORDOUW, A.C.G.
SIMS, E.J. *see* FOWLER, S.J.
SINGH, S.D. *see* ALLEN, D.J.
SITZMANN, J. *see* RICHTER, C.
SKARKE, C. *see* GRÖSCH, S.
SMIT, A.J. *see* LEFRANDT, J.D.
SMITH, A.J. The business of medicine, a history of Glaxo: 462
SMITH, M.T. *see* NISSEN, L.M.
SMITS, P. *see* MEIJER, P.
SNELL, P. *see* BUSS, N.
SONNIER, M. *see* TRÉLUYER, J.-M.
SORENSEN, H. *see* RIAHI, S.
SORENSEN, L. *see* TOFT, H.
SORIO, R. *see* TOFFOLI, G.
SOUKHOVA, N. *see* DESTA, Z.
SPINA, E. *see* SCORDO, M.G.
STACHULSKI, A.V. *see* ROW, E.
STALLARD, N. *see* WHITEHEAD, J.
STEFÁNSSON, S.B. *see* LINDHARDT, K.
STOLK, L.M. *see* DE WOLF, M.
STOLK, L.M.K. *see* BOERSMA, H.H.
STRICKER, B.H.Ch. *see* PENNING-VAN-BEEST, F.J.A.
STRICKER, B.H.Ch. *see* VAN DER LINDEN, P.D.
STRICKER, B.H.Ch. *see* VOORDOUW, A.C.G.
STRUIJKER-BOUDIER, H.A.J. *see* DE HOON, J.N.J.M.
STRUTHERS, A.D. *see* BUTLER, R.
STURKENBOOM, M.C.J.M. *see* VAN DER LINDEN, P.D.
STURKENBOOM, M.C.J.M. *see* VOORDOUW, A.C.G.
SUGIMOTO, K.-I. *see* HISHIKAWA, S.
SUPUTTAMONGKOL, Y., NEWTON, P.N., ANGUS, B., TEJA-ISAVADHARM, P., KEERATITHAKUL, D., RASAMEESORAJ, M., PUKRITTAYAKAMEE, S. & WHITE, N.J. A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria: 655
SVENSSON, J.-O. *see* ROH, H.-K.
SWART, M. *see* KRUIJTZER, C.M.F.
SWART, M., *see* CRUL, M.
SWOBODA, W. *see* SCHNEEWEISS, S.
SZABADI, E. *see* PRETORIUS, J.L.

TAALIKKA, M. *see* AHOKOSKI, O.
TAGAWA, M., KANO, M., OKAMURA, N., HIGUCHI, M., MATSUDA, M., MIZUKI, Y., ARAI, H., IWATA, R., FUJII, T., KOMEMUSHI, S., IDO, T., ITOH, M., SASAKI, H., WATANABE, T. & YANAI, K. Neuroimaging of histamine H_1-receptor occupancy in human brain by positron emission tomography (PET): A comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine: 501

TAMMINGA, W.J., WEMER, J., OOSTERHUIS, B., DE BOER, A., VRANCKX, S., DRENTH, B.F.H., DE ZEEUW, R.A., DE LEIJ, L.F.M.H. & JONKMAN, J.H.G. The influence of polymorphic drug metabolism (CYP2D6) on the pharmacotherapy of hospitalized psychiatric patients: 615P
TAN, H. *see* CRUL, M.
TANIRA, M.O.M., AL-NAZWAN, N., AL-BARWANI, H., AL ZAABI, M.A. & BAYOUMI, A.L. Pharmacogenomics of Omani population: preliminary data on the occurrence of mutant alleles at the CYP2D6 gene locus: 485P
TAYLOR, J.Y. *see* GARDNER-MEDWIN, J.M.
TEGEDER, I. *see* LÖTSCH, J.
TEJA-ISAVADHARM, P. *see* SUPUTTAMONGKOL, Y.
ten BOKKEL HUININK, W.W. *see* KRUIJTZER, C.M.F.
TETT, S.E. *see* NISSEN, L.M.
THABREW, I. *see* DE SILVA, H.A.
THIJSSEN, H.H.W. *see* DE HOON, J.N.J.M.
THIMISTER, P.W.L. *see* BOERSMA, H.H.
THOMPSON, R. *see* MORICE, A.H.
THORSSON, L., EDSBÄCKER, S., KÄLLÉN, A. & LÖFDAHL, C.-G. Pharmokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®: 529
TINGLE, M.D. *see* ZHOU, S.
TJIA, J. *see* GIBBONS, E.
TJIA, J.F. *see* REYNOLDS, H.E.
TODD, S. *see* WHITEHEAD, J.
TOFFOLI, G., CORONA, G., SORIO, R., ROBIEUX, I., BASSO, B., COLUSSI, A.M. & BOIOCCHI, M. Population pharmacokinetics and pharmacodynamics of oral etoposide: 511
TOFT, E. *see* RIAHI, S.
TOFT, H. *see* RIAHI, S.
TOFT, H., SORENSEN, L., MELLEMKJAER, J.H. & OLSEN, J.H. Risk of suicide in users of β-adrenoceptor blockers, calcium channel blockers, and angiotensin converting enzyme inhibitors: 313
TOMASKO, D. *see* GOLDBERG, M.R.
TRÉLUYER, J.-M., REY, E., SONNIER, M., PONS, G. & CRESTEIL, T. Evidence of impaired cisapride metabolism in neonates: 419
TSCHÖPE, D. *see* WEBER, A.-A.
TUCKER, G. BJCP – Down under: 487
TUCKER, G.T. *see* BOYLE, J.
TUCKER, G.T. *see* JOHNSON, T.N.
TUCKER, G.T. *see* YANG, J.S.
TUCKER, G.T. *see* YANG, J.S.
TUCKER, G.T., HOUSTON, J.B. & HUANG, S.-M. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential—towards a consensus: 107
TWISS, I.M., BURGGRAAF, J., DE KAM, M., COHEN, A.F. & VERMEIJ, P. Differences in gastrointestinal (GI) effects of several nitrogen containing bisphosphonates: 622P

URBIGKEIT, A. *see* LEFRANDT, J.D.

VAN AMELSVOORT, T. *see* COMPTON, J.
VAN BORTEL, L.M.A.B. *see* DE HOON, J.N.J.M.
VAN BOXTEL, C.J. *see* MULDER, W.M.C.
VAN BOXTEL, C.J. *see* RODER, E.
VAN DEN HOFF, O.P. *see* BUURMA, H.
VAN DER LEI, J. *see* VOORDOUW, A.C.G.
VAN DER LINDEN, P.D., STURKENBOOM, M.C.J.M., HERINGS, R.M.C., LEUFKENS, H.M.G. & STRICKER, B.H.Ch. Fluoroquinolones increase the risk of Achilles tendon rupture, especially in elderly patients on oral corticosteroids: 626P
VAN DER LINDEN, P.G. *see* VOORDOUW, A.C.G.
VAN DER POST, J., NOORDZIJ, L.A.W., BLAUW, G.J., DE KAM, M.L., PIETERS, M.S.M., COHEN, A.F. & VAN GERVEN, J.M.A. Cerebral hypoxia as a disease model for cognitive impairment: 625P
VAN GERVEN, J.M.A. *see* FRANSON, K.L.
VAN GERVEN, J.M.A. *see* VAN DER POST, J.
VAN GILST, W.H. *see* HILLEGE, H.L.
VAN GINNEKEN, E.E.M. *see* MEIJER, P.
VAN GROOTHEEST, K. *see* VAN PUIJENBROEK, E.P.
VAN HEERDE, W.L. *see* BOERSMA, H.H.
VAN KESTEREN, Ch., MATHOT, R.A.A., RAYMOND, E., ARMAND, J.P., BEIJNEN, J.H. & SCHELLENS, J.H.M. Design and validation of an optimal sampling strategy for assessment of E7070 exposure in a 1 h infusion study: 618P
VAN MEEGEN, E. *see* PENNING-VAN-BEEST, F.J.A.
VAN PUIJENBROEK, E.P., VAN GROOTHEEST, K., DIEMONT, W.L., LEUFKENS, H.G.M. & EGBERTS, A.C.G. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions: 579
VAN VELDHUISEN, D.J. *see* HILLEGE, H.L.
VANMOLKOT, F., DE HOON, J., BARRINGTON, P., PECK, R., DALLOW, N., WILLIAMS, P. & MCCOLM, J. Assessment of peripheral vascular effects of selective 5-$HT_{1B/1D}$-receptor agonists: comparison of different techniques: 619P
VAN'T VEER, L.J. *see* CRUL, M.
VASILAKIS-SCARAMOZZA, C. *see* JICK, H.
VASS, C. *see* RAINER, G.
VERMEIJ, P. *see* TWISS, I.M.
VOITH, B. *see* MÜCK, W.
VOORDOUW, A.C.G., VAN DER LINDEN, P.G., SIMONIAN, S., VAN DER LEI, J., STURKENBOOM, M.C.J.M. & STRICKER, B.H.Ch. Effectiveness of influenza vaccination in the elderly under everyday circumstances. A cohort study in general practitioner practices: 625P
VRANCKX, S. *see* TAMMINGA, W.J.
VYAS, Y. *see* GOLDBERG, M.R.

WALLEY, T. Dictionary of Pharmacoepidemiology.: 105
WALLIS, E.J. *see* JACKSON, P.R.
WALSH, D.S. *see* EDSTEIN, M.D.
WANG, J.-S. *see* WEN, X.
WATANABE, T. *see* TAGAWA, M.
WATKINS, C. *see* HUGHES, A.M.
WATSON, D.J. *see* RAHME, E.
WEBB, D.J. *see* MCENIERY, C.M.
WEBB, D.J. *see* WILKINSON, I.B.
WEBB, D.J. *see* WILKINSON, I.B.
WEBB, J.A., ROSTAMI-HODJEGAN, A., ABDUL-MANAP, R., HOFMANN, U., MIKUS, G. & KAMALI, F. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK–PD modelling analysis: 35
WEBER, A.-A., BRAUN, M., HOHLFELD, T., SCHWIPPERT, B., TSCHÖPE, D. & SCHRÖR, K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers: 333
WEITZEL, H. *see* RICHTER, C.
WEMER, J. *see* TAMMINGA, W.J.
WEN, X., WANG, J.-S., KIVISTÖ, K.T., NEUVONEN, P.J. & BACKMAN, J.T. *In vitro* evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9): 547
WENZEL, R.R., RÜTHEMANN, J., BRUCK, H., SCHÄFERS, R.F., MICHEL, M.C. & PHILIPP, TH. Endothelin-A receptor antagonist

© 2001 Blackwell Science Ltd

inhibits angiotensin II and noradrenaline in man: 151
WESTRUP, D. *see* KLINKHARDT, U.
WHITE, N.J. *see* SUPUTTAMONGKOL, Y.
WHITEHEAD, A. *see* WHITEHEAD, J.
WHITEHEAD, J., ZHOU, Y., STALLARD, N., TODD, S. & WHITEHEAD, A. Learning from previous responses in phase I dose-escalation studies: 1
WHYTE, I.M. *see* DAWSON, A.H.
WILEY, K.E. & DAVENPORT, A.P. Functional response of ghrelin, the novel endogenous ligand for the orphan GHS-receptor, in human artery: comparison with known vasodilators: 478P
WILKINS, E. *see* HOGGARD, P.G.
WILKINSON, I.B. & WEBB, D.J. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications: 631
WILKINSON, I.B. *see* MCENIERY, C.M.
WILKINSON, I.B., MCENIERY, C.M., BONGAERTS, K.H., MACCALLUM, H., WEBB, D.J. & COCKCROFT, J.R. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH_2-terminal 20 peptide (PAMP): 159
WILKS, M.F. *see* HALL, M.G.
WILLIAMS, B. *see* NISSEN, L.M.
WILLIAMS, D. & FEELY, J. Neglect of women in secondary prevention in Ireland—evidence for the yentyl syndrome: 470P
WILLIAMS, D., KELLY, A. & FEELY, J. Preferential prescribing of oral corticosteroids in Irish male asthmatic children: 319
WILLIAMS, D., NAISBITT, D., PIRMOHAMED, M. & PARK, K. Cytotoxic and apoptotic potential of felbamate and metabolites towards human peripheral white cells: 477P
WILLIAMS, K.M. *see* CAMPBELL, T.J.
WILLIAMS, P. *see* VANMOLKOT, F.
WILSON, A.M. *see* FOWLER, S.J.
WILSON, K. *see* ALLEN, D.J.
WILSON, S., JOHNSTON, A., COLLIER, D., FEDER, G., POULTER, N., CAULFIELD, M. Recruitment to clinical trials: does the amount of information mailed to patients influence response rate?: 468P
WINYARD, P. *see* HICKS, S.L.
WOLF, C.R. *see* ELSBY, R.
WOLZT, M. *see* RAINER, G.
WRAITH, E. *see* JOHNSON, T.N.

YAMAURA, Y. *see* SENDA, C.
YANAI, K. *see* TAGAWA, M.
YANG, J.S., ROSTAMI-HODJEGAN, A. & TUCKER, G.T. Prediction of fluconazole interaction with midazolam and triazolam: incorporating population variability: 484P
YANG, J.S., ROSTAMI-HODJEGAN, A. & TUCKER, G.T. Prediction of ketoconazole interaction with midazolam, alprazolam and triazolam: incorporating population variability: 472P
YANG, Q. *see* LIU, M.-H.
YASAR, U. *see* SCORDO, M.G.
YEO, K.R. & YEO, W.W. Lipid-lowering therapy for patients with diabetes mellitus: data from the health survey for England 1998: 486P
YEO, W.W. *see* YEO, K.R.

ZANNAD, F. *see* LEFRANDT, J.D.
ZHANG, S.-Q., HAI, T.N., ILETT, K.F., HUONG, D.X., DAVIS, T.M.E. & ASHTON, M. Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers: 377
ZHAO, L. *see* GOLDBERG, M.R.
ZHOU, H.-H. *see* LIU, Z.-Q.
ZHOU, S., CHIN, R., KESTELL, P., TINGLE, M.D. & PAXTON, J.W. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMSAA) by human liver microsomes: 129
ZHOU, Y. *see* WHITEHEAD, J.

SUBJECT INDEX

This index was compiled from the keywords
(P = Proceedings, S = Supplement)

α_1-adrenergic receptor, 279
Abacavir, 466P
Absorption, 699
ACE inhibition, 621P
Acenocoumarol, 616P
Acetominophen, 573
Acetylcysteine, 573
Achilles tendon rupture, 626P
Acute lymphoblastic leukaemia, 539
Adenosine-5′-triphosphate, 620P
Adrenal suppression, 93
Adrenergic desensitization, 289
Adrenomedullin, 159, 165
Adverse drug reaction, 196
Adverse drug reactions, 77, 337
Adverse event, 229
Adverse events, 185
Ageing, 647
Airway hyperresponsiveness, 245
AJ-2615, 279
Alcohol, 455, 467P
Alcoholic liver disease, 469P
Allostery, 53
Alosetron, 596
Alprazolam, 472P
Alternative medicine, 587
Alzheimer's disease, 647
Amlodipine, 687
Amphotericin B, 671
Analgesia, 35
Analgesic use, 693
Angiotensin enzyme inhibitors, 313
Angiotensin I, 145
Angiotensin II, 151, 165
Antacids, 341
Antiarrhythmic drugs, 21S
Antibacterial drugs, 616P
Anti-cancer, 129
Anticholinergic, 409
Antidepressants, 45S
Antidepressive agents, 179
Antiepileptic drugs, 11S
Antimetabolites, 75S
Antimicrobial agents, 35S
Antipsychotics, 45S
Antituberculous drugs, 611
Arginine vasopressin, 165
Aromatase inhibitor, 702
Artemether, 655
Artemisinin, 377
Arterial, 45
Arteries, 159
Arteriolar, 45
Artesunate, 377, 655
Aspirin, 297, 563
Asthma, 245, 319, 529
Asthma drugs, 121
Atrial natriuretic peptide, 165
β_2-adrenoceptor agonist, 245
β-adrenoceptor blockers, 313
Beclomethasone, 93
Benzodiazepine, 521
Benzodiazepines, 455
Betaine, 474P
Biliary excretion, 65
Bioassay, 655
Bioavailability, 457, 619P, 655, 705
Bioequivalence, 245, 387
Bisphosphonates, 622P
Bladder hyperthermia, 273
Blood flow, 631
Book review, Dictionary of pharmacoepidemiology, 105
Book review, Adverse drug reactions, 461
Book review, Meyler's side-effects of drugs, 461
Book review, The business of medicine, a history of Glaxo, 462
Book review, Antimalarial chemotherapy: Mechanisms of action, resistance and new directions in drug discovery, 463
Book review, Anxiolytics, 463
Book review, Pharmacology of cerebral ischemia, 613
BQ-123, 151
BQ-788, 151
Breast milk, 708
Bronchodilator, 245
Budesonide, 529

Caffeine, 601
Calcium channel antagonist, 179
Calcium channel blockers, 210, 313
Cancer, 511, 617P
Capsaicin, 365
Cardiovascular functions, 322
Case control study, 179, 489
Cerebral hypoxia, 625P
Cerivastatin, 213
Chenodeoxycholic acid,699
Child, 77
Children, 319, 671
(+)-chlorpheniramine, 501
Chlorzoxazone, 555
Chronic pain, 693
Chronopharmacokinetics, 65
Cisapride, 399, 419
Citric acid, 365
Clinical interpretation, 5S
Clinical Pharmacology, 9, 623P
Clinical pharmacy, 85
Clinical trials, 468p
Clopidrogel, 333
Clozapine, 322
Cognitive function, 647
Cognitive impairment, 625P
Combination, 655
Community pharmacy services, 85
Complications, 563
Compound 48/80, 624P
Concentration-effect relationship, 25
Conference report, 107
Conformity assessment, 229
Congestive heart failure patients, 25
Continual reassessment method, 1
Continuing medical education, 9
Continuing professional development, 9
Controlled release, 409
Coronary artery bypass grafting,279
Corticosteroids, 626P
Cost, 185
COST B15, 118
Cotrimoxazole, 611
Cough reflex, 365
Coumarin, 357
Critical flicker fusion frequency, 322
CYP1A2, 596
CYP2C, 349
CYP2C19, 96, 349
CYP2C9, 349, 547
CYP2D6, 485P, 615P
CYP2D6 genotype, 265
*CYP2D6*10*, 100
CYP2E1, 555
CYP3A, 475P, 555
CYP3A4, 419
CYP3A7, 419
Cytochrome P450, 489, 547
Cytochrome P450 1A2, 601
Cytokine, 489
Cytosine arabinoside, 75S
Cytosolic enzymes, 53
Cytotoxic drugs, 75S

Depression, 313
Developing country, 103S
Device regulation, 229
Diabetes mellitus, 486P
Diazepam, 521
Dihydroartemisinin, 377
Dihydrocodeine, 35
Dihydroergotamine, 45
Dihydromorphine, 35
Dipropionate, 93
Dissemination of information 579
Ditropan XL, 409
DMXAA, 129
Dose-finding, 1
Drug interaction, 129
Drug interactions, 69, 616P
Drug metabolism, 419
Drug metabolizing enzymes, 53
Drug related hospitalization, 196
Drug response, 489

© 2001 Blackwell Science Ltd

Drug safety, 439
Drug-drug interactions, 53
Drug-related problems, 85, 622P
Dry mouth, 409

E7070, 618P
Ebastine, 201, 501
EEG, 521
Effect compartment, 25
Elderly, 625P
Electrocardiographic effects, 201
Electroencephalagraphy, 521
Enantiomers, 681
Endothelial dysfunction, 327
Endothelin antagonist, 151
Endothelium, 145
Epidemiology, 179, 307, 313, 563
Epilepsy, 193, 477P
ERP, 521
Erwinia asparaginase, 433
Etoposide, 511
Evaluation studies, 85
Event-relatedpotential, 521

Factor analysis, 137
Farnesyltransferase inhibitor, 617P
Felbamate, 477P
Finrozole, 702
First-in-man, 1
Flomoxef, 65
Fluconazole, 456, 484P
Fluorescence resonance energy transfer, 711
Fluoroquinolones, 626P
Fluorouracil, 75S
Fluoxetine, 96
Fluticasone, 529
Fluticasone proprionate, 93, 457
FMO, 53
Forearm blood flow, 159
Front-line therapy, 433
Fruit juice, 475P
Furazolidone, 205
Furazolidone bioavailability, 205

Gastrointestinal, 185
Gastrointestinal effects, 622
Gene dose, 96
Genotype, 96
Gentamicin, 616P
GF 120918, 619P
γ-glutamylcysteine, 478P
γ-glutamylcysteine synthetase,482P
Ghrelin, 478P
Glaucoma, 210
Glicazide, 456
Glucuronidation, 605
Glutathione, 482P
GPIIb/IIIa-antagonists, 297
Grapefruit juice, 216, 399

H.p.l.c., 273
Haematological toxicity, 511
Haemodynamics, 25
Haloperidol, 265, 322
Hand grip exercise, 485P
Healthy, 529
Healthy volunteers, 25
Helicobacter pylori, 205
Heparin, 297
Herbal medicine, 587
Herbal preparation, 469P
Hetero-activation, 53
Heterologous expression, 53
Histamine, 624P
Histamine H_1-receptor, 501
HIV, 465P, 466P, 480P, 481P, 611
Homo-activation, 53
Homocysteine, 327, 474P
Homocysteinuria, 474P
HPPD inhibitors, 169
HT-1, 169
5-$HT_{1B/1D}$-receptor agonists, 619P
Human, 53, 165, 601
Human liver microsomes, 100, 129
Human tissue, 605
Human microsomal protein, 471P
Hydrofluoroalkane inhalers, 93
Hydroxymethylglutaryl-Co A inhibitors, 439
Hypercalcaemia, 341
Hyperlipidaemia, 439
Hypertriglyceridaemia, 626P

I.m. administration, 433
I.v. administration, 433
Ibuprofen, 387
ICD10, 337
Immediate concurrent feedback, 427
Immunogenicity, 483P
Immunosuppressant drugs, 61S
Implementing guidelines, 427
In vitro/*in vivo* predictions, 53
Induction, 377
Inflammation, 121, 466P
Influenza vaccine, 625P
Infusions, 573
Inhalation cough challenge,365
Inhaled drugs, 716
Inhibition, 377, 547
Inhibitory quotient, 89S
Inorganic nitrate, 474P
Interaction, 213, 297, 456, 472P, 484P, 547, 587
Interethnic differences, 447
Internal mammary artery, 279
Intranasal, 521
Intravesical chemotherapy, 273
Intrinsic clearance, 605
Intussusception, 451
Iontophoresis, 17, 289
Irreversibility, 333
Ivory Coast, 611

Ketoconazole, 472P

Lamivudine, 466P
Laser Doppler fluximetry, 17, 327
L-asparagine depletion, 433
Leukotriene D_4, 466P
LightCycler, 711
Lipid lowering drugs, 307
Lipid-lowering therapy, 486P
Lithium, 45S
Lithium counter-transport, 468P
Liv.52, 469P
Live attenuated polio vaccine, 451
Liver transplant, 213
Losartan, 447
Low doses, 705
Low molecular weight heparin, 708
Lung cancer, 357
Lung distribution, 716
Lymphoblastic anaemia, 476P

Maintenance therapy, 473P
Malaria, 655, 663
Medical devices, 229
Medical Devices Agency, 229
Medical students, 623
Medication errors, 85, 573
Mephenytoin, 349
Mercaptopurine, 75S, 539
6-mercaptopurine, 476P
Mesotrione, 169
Meta-analysis, 77, 439, 563
Metabolic clearance, 53
Metformin, 137
Methadone, 473P, 681
Methicillin resistant *Staphylococcus aureus* (MRSA), 427
Methotrexate, 75S
Metoprolol, 69, 237
Mexiletine, 100
Microvascular, 327
Midazolam, 472P, 484P, 555
Migraine headache, 69
Migraine prophylaxis, 237
Milk, 681
Monitoring, 196
μ-opioid receptor, 711
MPV-2213ad, 702
99mTc-phenothioate-Annexin V, 617P
Multidisciplinary pain centre, 693
Multidrug resistance-associated protein, 481P
Mycophenolic acid, 605
Myocardial infarction, 179, 621P

Nadolol, 69
Nasal, 521
Neonates, 419, 616P
Neutral endopeptidase, 159
New approach directives, 229
Nicotine, 357
Nitrendipine, 699
Nitric oxide, 145
Non-inferiority, 219, 221, 223
NONMEM, 663
Non-nucleoside reverse transcriptase inhibitors, 480P
Noradrenaline, 151, 289, 687
Norfluoxetine, 96
Notified bodies, 229
NSAIDs, 185

NTBC, 169
Nucleoside triphosphate ratios, 466P

Obituary, Professor J. Petrie, 629
Ocular blood flow, 210
Oestradiol, 702
Oestrogen, 647
Omani population, 485P
Omeprazole, 205, 216, 349
Opioid analgesics, 693
Oral corticosteroids, 319
OROS, 409
Orphan GHS receptor, 478P
Outpatient clinic, 622P
Overdose, 97S
Oxybutynin, 409

P450, 53
Pain, 35, 289
PAMP, 159
Paracetamol, 573
PEG300, 521
Peptic ulcer, 205
Perindopril, 25
P-glycoprotein, 465P, 481P
Pharmacists, 85
Pharmacodynamics, 69, 169, 201, 511
Pharmacoeconomics, 193
Pharmacoenhancement, 89S
Pharmacogenetics, 345
Pharmacogenomics, 345, 485P
Pharmacokinetics, 45, 69, 96, 169, 255, 377, 387, 399, 529, 596, 616P, 617P, 655, 681, 702
Pharmacotherapy, 615P
Pharmacovigilance, 196, 337, 579
Phenprocoumon, 616P
Phenytoin, 349
PK-PD modelling, 25, 35
Plasma cortisol, 529
Plasma lactate, 137
Plasma t-PA, 626P
Plasmodium falciparum, 655
Platelets, 333
Poisoned patient, 97S
Poisoning, 470P
Polyethylene glycol 300, 521
Polymorphic drug metabolism, 615P
Polymorphism, 489P, 711
Polymorphisms, 349
Poor metabolizers, 447
Population pharmacokinetics, 511, 663, 671
Population variability, 472P
Population-based, 196
Positron emission tomography, 501
Potassium channels, 620P
P-Pharm, 671
Prescribing practices, 693
Prescription, 307
Prescriptions, 85
Primary Raynaud's phenomenon, 17
Prolactin, 322
Propranolol, 69, 237
Prospective studies, 77
Protease inhibitors, 89S, 480P, 481P
Psychiatric patients, 625P
Psychotropic, 45S
Puerperium, 708
Pulse, 467P
Pupil, 322
Pyrrolidine dithiocarbamate, 482P

QTc interval, 201
Quality control, 573

R115777, 617P
Rate-pressure product, 687
Receptor occupancy, 501
Recruitment, 468P
Red blood cells, 539
Red wine, 475P
Reference values, 471P
Renal function, 621P
Reproducibility, 485P, 624P
Response rate, 468P
Revalidation, 9
Risk, 587
Ritonovir, 255
Rizatriptan, 69
Safety, 587
Salivation, 322
Salt, 468P
Saquinavir, 255
Schizophrenic patients, 265
Seasonal variation, 17
Second exposure, 433
Secondary prevention, 470P
Sedation, 322
Serotonin, 179
Serotonin uptake inhibitors, 179
Serum transaminase, 611
Sigmoid model, 25
Signal selection, 579
Single nucleotide polymorphism, 711
Skin, 466P
Skin microcirculation, 151
Skin temperature, 17
Smoking, 145
S-nitrosothiols, 474P
Soft gelatin capsule, 255
Solid tumours, 618P
Sotalol, 715
Spirometry, 245
Spontaneous reporting system, 579
Sputum cell counts, 121
Stereoselectivity, 399
Stress responses, 687
Suicide, 313
Sulphamethoxazole, 456,483P
Superficial transitional cell carcinoma, 273
Superiority, 219, 221, 223
Systematic review, 77
Systemic absorption, 273
Systemic clearance, 619P

Tachyphylaxis, 479P
Tacrolimus, 213
Tafenoquine, 663
Target concentration interventation, 55S
Teaching resource centre, 623P
Terfenadine, 201
Thailand, 655
Theophylline, 596
Therapeutic drug monitoring, 1S, 3S, 5S, 11S, 21S, 35S, 45S, 55S, 61S, 75S, 89S, 97S, 103S, 193, 480P, 481P
Therapeutic management, 5S
Therapeutics, 9
Thermal hyperalgesia, 289
Thioguanine, 539
6-thioguanine, 476P
6-thioguanine nucleotide, 476P
Thioguanine nucleotides, 539
Thiopurine methyltransferase, 539
Tobacco smoke, 357
Tolbutamide, 349
Topotecan, 619P
Toxicity, 97S
Trial design, 237
Triazolam, 472P, 484P
Triketones, 169
Tropisetron, 705
Trough enzyme activities, 433
T-wave, 715
Type 2 diabetes, 137
Tyramine pressor test, 479P
Tyrosine, 169

UDP-glucuronosyltransferase, 478P
Urinary incontinence, 409
Ursodeoxycholic acid, 699
U-wave, 715

Valproic acid, 547
Vancomycin, 427
Vascular regulation, 485P
Venous occlusion plethysmography, 631
Verapamil, 687
Vigilance reporting, 229
Visual field, 210
Volunteers, 705

Warfarin, 349, 447
Whole body plethysmography, 245
Wine, 455, 467P

Yellow oleander, 470P
Yentyl syndrome, 470P